# KMT2D Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- KMT2D encodes a large histone methyltransferase essential for depositing H3K4me1 marks at active and primed enhancer regions, playing a critical role in transcriptional regulation and cellular differentiation.
- Germline loss-of-function mutations in KMT2D cause Kabuki syndrome type 1, a multisystem disorder characterized by distinctive facial features, developmental delay, and congenital malformations, with mutations in exon 39 defining a distinct clinical entity.
- Somatic mutations in KMT2D are prevalent across numerous cancers, including DLBCL, FL, and lung squamous cell carcinoma, where it acts as a context-dependent tumor suppressor, but can also promote oncogenesis in specific settings.
- KMT2D's function is integrated into key signaling pathways including PI3K/AKT/mTOR, Wnt/β-catenin, and MEK/ERK, and it is crucial for immune cell function, particularly in T cell development and antiviral responses.
- Therapeutic strategies are emerging, including KMT2D inhibitors for cancers where it acts as an oncogene, and synthetic lethality approaches targeting compensatory pathways in KMT2D-deficient tumors, such as KDM5 inhibition in lymphomas.

---

## Executive Summary & Key Metadata

The **KMT2D** gene (Lysine Methyltransferase 2D), historically designated *MLL2* (Mixed-Lineage Leukemia 2) and *MLL4* in some nomenclature systems, encodes a large (~593 kDa) histone-modifying enzyme that serves as the primary mammalian H3K4 mono-methyltransferase at enhancer regions. KMT2D functions as a core component of the COMPASS (Complex of Proteins Associated with Set1) family of complexes, catalyzing the deposition of mono-methylation at histone H3 lysine 4 (H3K4me1), a chromatin mark that demarcates active and primed enhancers. Germline loss-of-function mutations in KMT2D cause **Kabuki syndrome type 1 (KS1; OMIM #147920)**, a multisystem congenital malformation disorder. Somatic mutations in KMT2D are among the most frequent genetic alterations across a broad spectrum of human malignancies, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), medulloblastoma, breast cancer, lung squamous cell carcinoma, and pancreatic cancer. The gene product is a context-dependent tumor suppressor, yet in certain oncogenic contexts, KMT2D exhibits tumor-promoting activities, underscoring its complex, cell-type-specific biology.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | KMT2D |
| **UniProt Accession** | O14686 |
| **Representative PDB ID** | True (see Section 2) |
| **Chromosomal Locus** | 12q13.12 (GRCh38: chr12:49,018,978-49,060,794; minus strand) |
| **Primary Molecular Function** | Histone H3 lysine 4 (H3K4) mono/di-methyltransferase; enhancer regulation; transcriptional co-activation |
| **Disease & Pathology Associations** | Kabuki syndrome type 1 (germline); DLBCL, FL, medulloblastoma, breast cancer, lung SCC, pancreatic cancer, prostate cancer (somatic) |
| **Protein Length** | 5,537 amino acids (isoform 1) |
| **Molecular Weight** | ~593 kDa |
| **Subcellular Localization** | Nucleus (chromatin-associated) |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Coordinates and Gene Architecture

The KMT2D gene is located on the **long arm of chromosome 12 at band q13.12** (12q13.12). In the GRCh38/hg38 assembly, the gene spans approximately **41.8 kilobases** of genomic DNA, oriented on the **minus (reverse) strand** (chr12:49,018,978–49,060,794). The gene comprises **54 exons**, with the translational start site located in exon 2 and the termination codon in exon 54. The coding sequence spans approximately 16.6 kb, encoding a protein of 5,537 amino acids.

The KMT2D locus resides within a gene-dense region of chromosome 12 that includes several other disease-relevant genes. The neighboring genomic landscape includes *ANAPC7* (anaphase-promoting complex subunit 7) and *KMT2D*'s paralog *KMT2C* (MLL3) on chromosome 7q36.1, with which KMT2D shares partial functional redundancy. The promoter region of KMT2D contains a canonical CpG island spanning approximately 1.2 kb surrounding the transcription start site (TSS). This CpG island exhibits differential methylation patterns in cancer, with hypermethylation associated with transcriptional silencing in non-small cell lung cancer (NSCLC).

### 1.2 Promoter Architecture and Regulatory Elements

The KMT2D promoter lacks a canonical TATA box but contains multiple Sp1-binding sites and a high GC content (~65%), characteristic of housekeeping and developmentally regulated genes. Chromatin immunoprecipitation sequencing (ChIP-seq) data from ENCODE reveal that the promoter is marked by H3K4me3 and H3K27ac in most cell types, indicating constitutive active transcription. However, the promoter also harbors binding sites for lineage-determining transcription factors, including GATA1 in erythroid cells, where KMT2D is recruited to enhancers in a GATA1-dependent manner.

The gene body contains multiple enhancer elements, particularly within introns 1, 2, and 39. Notably, **exon 39** encodes a functionally critical region of the protein, and mutations clustering in this exon define a distinct clinical entity with a phenotype overlapping but distinguishable from classic Kabuki syndrome. The intronic enhancers within intron 1 have been shown to interact with the promoter via chromatin looping, as demonstrated by Hi-C data in lymphoblastoid cell lines.

### 1.3 Alternative Splicing and Isoforms

KMT2D undergoes complex alternative splicing, generating multiple transcript variants. The canonical transcript (ENST00000306029.9) encodes the full-length 5,537-amino-acid protein. At least **five additional protein-coding isoforms** have been annotated in Ensembl, with variations primarily affecting the N-terminal region and the low-complexity domains (LCDs). A notable isoform lacking exon 2 (which contains the start codon) utilizes an alternative downstream start site, producing a truncated protein of approximately 4,800 amino acids that retains the C-terminal SET domain but lacks several N-terminal regulatory motifs.

Alternative splicing of exon 39 generates isoforms with or without a 45-amino-acid insertion that modulates the interaction with the NCOA6 (ASC-2) co-activator complex. The expression of these isoforms is tissue-specific, with the exon 39-containing isoform enriched in brain and testis, whereas the exon 39-skipped isoform predominates in hematopoietic tissues. Additionally, the 3' untranslated region (UTR) of KMT2D contains multiple microRNA (miRNA) binding sites, including those for miR-204-5p, which has been shown to downregulate KMT2D expression in gastric cancer.

### 1.4 Transcriptional Regulation and Epigenetic Control

KMT2D expression is itself subject to epigenetic regulation. The long non-coding RNA (lncRNA) **NORAD** (non-coding RNA activated by DNA damage) functions as a competing endogenous RNA (ceRNA) that sequesters miR-204-5p, thereby derepressing KMT2D translation in gastric cancer cells. This NORAD/miR-204-5p/KMT2D regulatory axis illustrates the multilayered control of KMT2D expression.

Post-translational regulation of KMT2D protein stability is mediated by the E3 ubiquitin ligase **FBXW7**, which recognizes a conserved Cdc4 phosphodegron motif and targets KMT2D for proteasomal degradation in diffuse large B-cell lymphoma cells. Conversely, the protein **DBC1** (Deleted in Breast Cancer 1) acts as a positive regulator of KMT2D, stabilizing the protein and promoting its chromatin association at enhancer regions. The methyltransferase **SMYD2** methylates KMT2D at lysine residues, modulating its stability and activity in hormone-dependent breast cancer.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

KMT2D is a massive, multi-domain protein of 5,537 amino acids. Its domain architecture, from N-terminus to C-terminus, comprises the following functional modules:

| **Domain/Motif** | **Approximate Residues** | **Function** |
|---|---|---|
| N-terminal low-complexity domain (LCD1) | 1–400 | Phase separation; transcriptional condensate formation |
| PHD finger 1 (Plant Homeodomain) | 1,200–1,260 | Recognition of H3K4me0; chromatin targeting |
| HMG-box (High Mobility Group) | 1,400–1,480 | DNA binding; architectural chromatin factor |
| PHD finger 2 | 1,600–1,660 | Histone recognition |
| FY-rich domain (FYR-N) | 2,000–2,200 | Protein-protein interactions |
| FY-rich domain (FYR-C) | 2,200–2,400 | Protein-protein interactions |
| PHD finger 3 | 2,500–2,560 | Histone recognition |
| PHD finger 4 | 2,700–2,760 | Histone recognition |
| Low-complexity domain (LCD2) | 3,000–3,400 | Phase separation; transcriptional condensate formation |
| PHD finger 5 | 3,500–3,560 | Histone recognition |
| PHD finger 6 | 3,700–3,760 | Histone recognition |
| FY-rich domain (FYR-C) | 4,000–4,200 | Protein-protein interactions |
| SET domain (Su(var)3-9, Enhancer of zeste, Trithorax) | 5,100–5,400 | Catalytic H3K4 methyltransferase activity |
| Post-SET domain | 5,400–5,537 | Zinc coordination; catalytic regulation |

### 2.2 The Catalytic SET Domain

The **SET domain** (residues ~5,100–5,400) constitutes the catalytic core of KMT2D, responsible for the transfer of a methyl group from S-adenosyl-L-methionine (SAM) to the ε-amino group of lysine 4 on histone H3. The SET domain adopts the canonical β-sheet-rich fold characteristic of the SET family of methyltransferases, comprising a series of antiparallel β-strands that form a pseudo-knot structure. The active site contains a conserved **NHxCxPN** motif that coordinates a zinc ion essential for structural integrity.

The post-SET domain (residues 5,400–5,537) contains a Cys4-type zinc-binding motif that forms a claw-like structure wrapping around the SET domain, contributing to the formation of the substrate-binding channel. The KMT2D SET domain exhibits a strong preference for **mono-methylation** of H3K4, producing H3K4me1, with weaker di-methylation (H3K4me2) activity and negligible tri-methylation (H3K4me3) activity. This product specificity distinguishes KMT2D from the H3K4me3-specific methyltransferases KMT2A and KMT2B (MLL1 and MLL2).

### 2.3 PHD Fingers and Chromatin Reading

The six PHD fingers of KMT2D serve as chromatin-reading modules that recognize specific histone modifications. PHD1 and PHD2 bind unmodified H3K4 (H3K4me0), facilitating the recruitment of KMT2D to nucleosomes that have not yet been methylated, thereby enabling processive methylation. PHD3–PHD6 exhibit more promiscuous binding, recognizing both unmodified and methylated H3K4, as well as other histone marks. The combinatorial action of these PHD fingers ensures that KMT2D is targeted to appropriate genomic loci and that its catalytic activity is spatially and temporally regulated.

### 2.4 Low-Complexity Domains and Phase Separation

Recent work has identified two extensive **low-complexity domains (LCDs)** within KMT2D (residues 1–400 and 3,000–3,400) that mediate **liquid-liquid phase separation (LLPS)**. These LCDs are enriched in serine, proline, and glutamine residues and are capable of forming dynamic, membrane-less nuclear condensates. In pancreatic cancer cells, the LCDs of KMT2D drive the formation of transcriptional condensates at enhancer regions, concentrating RNA Polymerase II and transcriptional co-activators to facilitate gene expression. This phase-separation behavior links KMT2D function to the emerging paradigm of transcriptional regulation via biomolecular condensates.

### 2.5 Structural Insights from Cryo-EM and X-ray Crystallography

While a full-length structure of KMT2D remains elusive due to its size and intrinsic disorder, high-resolution structures of individual domains have been determined. The SET domain of KMT2D has been solved by X-ray crystallography in complex with SAM and a histone H3 peptide (PDB: 6KQK and related entries), revealing the molecular basis of its H3K4me1 product specificity. The structure shows that a tyrosine residue within the SET domain forms a hydrogen bond with the backbone carbonyl of H3K4, orienting the substrate for mono-methylation while sterically hindering access for tri-methylation.

Cryo-electron microscopy (cryo-EM) structures of the KMT2D-containing COMPASS complex have been resolved at moderate resolution, revealing the overall architecture of the ~1 MDa complex. The complex comprises the core subunits WDR5, RBBP5, ASH2L, and DPY30, which assemble around the KMT2D catalytic domain. WDR5 binds to the conserved **Win motif** (WDR5 interaction motif) located N-terminal to the SET domain, an interaction essential for complex assembly and catalytic activity.

### 2.6 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load KMT2D (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O14686)

The interactive visualizer provides a comprehensive 3D representation of the KMT2D protein, including the domain architecture, the catalytic SET domain, PHD fingers, and low-complexity regions. Users can explore the spatial arrangement of functional domains, examine the electrostatic surface potential, and visualize predicted post-translational modification sites. The visualizer integrates AlphaFold2 predictions for the full-length protein alongside experimentally determined structures of individual domains, enabling a multi-scale structural analysis.

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The COMPASS Complex and Enhancer Regulation

KMT2D functions exclusively as the catalytic subunit of a **COMPASS-like complex** that includes the core structural components WDR5, RBBP5, ASH2L, and DPY30, along with the accessory subunits NCOA6 (ASC-2), PTIP (PAXIP1), PAXIP1-AS1, and the histone H3K27 demethylase UTX (KDM6A). The association with UTX is particularly significant, as it couples H3K4me1 deposition with H3K27me3 demethylation, coordinating the transition from poised to active enhancer states.

The primary molecular function of KMT2D is the **mono-methylation of H3K4 at enhancer regions**, a chromatin mark that is deposited on nucleosomes flanking active and primed enhancers. H3K4me1 serves as a docking site for effector proteins, including the chromatin reader **YBX1**, which recognizes H3K4me1 and facilitates the recruitment of additional transcriptional activators. In triple-negative breast cancer, KMT2D-mediated H3K4me1 recruits YBX1 to the c-Myc promoter, driving c-Myc expression and tumor progression.

### 3.2 KMT2D in Transcriptional Regulation

KMT2D exerts its transcriptional effects through multiple mechanisms:

1. **Enhancer activation**: By depositing H3K4me1, KMT2D marks enhancers for activation, facilitating the recruitment of co-activators such as p300/CBP, which deposit H3K27ac.
2. **Super-enhancer regulation**: KMT2D is enriched at super-enhancers, large clusters of enhancers that drive high-level expression of cell-identity genes. Loss of KMT2D leads to diminished super-enhancer activity and reduced expression of lineage-defining transcription factors.
3. **Pioneer factor cooperation**: KMT2D cooperates with pioneer transcription factors such as GATA1, p63, and FOXO3 to establish enhancer accessibility at target loci. In erythroid cells, KMT2D is an essential cofactor for GATA1, mediating H3K4me1 deposition at GATA1-bound enhancers and coordinating erythroid gene expression.
4. **Transcriptional condensates**: The LCDs of KMT2D promote phase separation, concentrating transcriptional machinery at enhancer clusters to amplify gene expression.

### 3.3 KMT2D in Cellular Signaling Pathways

#### 3.3.1 PI3K/AKT/mTOR Pathway

KMT2D intersects with the PI3K/AKT/mTOR signaling axis at multiple levels. In prostate cancer, KMT2D expression is regulated by PI3K signaling, and KMT2D is required for the growth of PTEN-null, AR-dependent prostate cancer cells. Mechanistically, KMT2D maintains androgen receptor (AR) signaling by sustaining the expression of AR target genes, and KMT2D loss sensitizes prostate cancer cells to AKT inhibition. In mammary epithelial cells, activated PI3K cooperates with KMT2D to induce Arp2/3-dependent cell migration, linking KMT2D to cytoskeletal remodeling and metastasis.

#### 3.3.2 Wnt/β-Catenin Signaling

KMT2D modulates Wnt/β-catenin signaling in multiple contexts. In dental epithelial cells, KMT2D deficiency disturbs cell proliferation and cell cycle progression partially through Wnt signaling. In growth plate chondrocytes, knockdown of Kmt2d activates the Akt/β-catenin signaling pathway, leading to impaired chondrocyte proliferation and short stature, a hallmark of Kabuki syndrome.

#### 3.3.3 MEK/ERK Signaling

Phosphoproteomic analyses have revealed that KMT2D is a substrate of the MEK/ERK signaling cascade. ERK-mediated phosphorylation of KMT2D modulates its chromatin association and methyltransferase activity, providing a direct link between growth factor signaling and epigenetic regulation. This phosphorylation-dependent regulation of KMT2D represents a mechanism by which extracellular signals are transduced into durable chromatin changes.

#### 3.3.4 Glucocorticoid Receptor Signaling

KMT2D maintains cellular glucocorticoid responsiveness by shielding the glucocorticoid receptor (GR) from proteasomal degradation. In lymphocytes, KMT2D interacts with GR and prevents its ubiquitination and degradation, thereby sustaining GR protein levels and glucocorticoid-induced apoptosis. This function has therapeutic implications for glucocorticoid-resistant hematological malignancies.

#### 3.3.5 Mitochondrial Respiration and Metabolism

Loss of KMT2D function leads to deregulation of mitochondrial respiration. Fibroblasts from Kabuki syndrome patients with KMT2D mutations exhibit reduced oxygen consumption rates, decreased ATP production, and altered expression of mitochondrial electron transport chain components. This mitochondrial dysfunction may contribute to the multisystem manifestations of Kabuki syndrome, including growth retardation and neurological impairment. Additionally, KMT2D deficiency alters ribosomal protein expression, and ketogenic diet intervention can partially rescue these abnormalities in Kabuki syndrome models.

### 3.4 Protein-Protein Interaction Networks

KMT2D participates in extensive protein-protein interaction networks, as catalogued in BioGRID and STRING databases. Key interacting partners include:

- **Core COMPASS subunits**: WDR5, RBBP5, ASH2L, DPY30
- **Enhancer-associated factors**: NCOA6, PTIP, UTX/KDM6A, p300/CBP
- **Transcription factors**: GATA1, p63, FOXO3, AR, GR, EBF2
- **Chromatin readers**: YBX1, KLLN
- **E3 ubiquitin ligases**: FBXW7 (mediates degradation)
- **Stabilizing factors**: DBC1, SMYD2

The interaction between KMT2D and **EBF2** (Early B-cell Factor 2) is particularly notable in pancreatic cancer, where EBF2 binds H3K4me1 and recruits KMT2D to the KLLN promoter, suppressing tumor progression. This interaction exemplifies the cooperation between KMT2D and sequence-specific transcription factors in enhancer-mediated gene regulation.

### 3.5 KMT2D in Immune Cell Function

KMT2D plays critical roles in the immune system, particularly in lymphocyte development and function:

1. **T follicular helper (TFH) cells**: KMT2D coordinates antiviral CD4+ T cell responses by opposing effects on TFH and cytotoxic gene expression. KMT2D promotes TFH differentiation while suppressing cytotoxic gene programs, balancing humoral and cell-mediated immunity.
2. **CD8+ T cells**: KMT2D regulates naive CD8+ T cell generation and activation-induced survival. KMT2D-deficient CD8+ T cells exhibit impaired survival upon activation, compromising antiviral immunity.
3. **Regulatory T cells (Tregs)**: KMT2D is required for Foxp3 gene expression and Treg generation, linking KMT2D to immune tolerance.
4. **T cell activation and integrin expression**: KMT2D regulates T cell activation, localization, and integrin expression. KMT2D-deficient T cells exhibit altered integrin expression, impairing thymic egress and peripheral trafficking.
5. **B cell development**: KMT2D sustains a gene expression program that represses B cell lymphoma development. In germinal center B cells, KMT2D maintains the expression of tumor suppressor genes and prevents aberrant activation of oncogenic programs.
6. **Macrophage polarization**: KMT2D induces M1 macrophage polarization to repress non-small cell lung cancer progression via transcriptional activation of ITGAL.

### 3.6 KMT2D in Development

KMT2D is essential for embryonic development, as evidenced by the severe congenital malformations in Kabuki syndrome. Key developmental roles include:

- **Neural crest cell formation and migration**: KMT2D is required for neural crest cell formation and migration, explaining the craniofacial abnormalities in Kabuki syndrome.
- **Heart development**: KMT2D loss of function affects heart development in Xenopus laevis, recapitulating the congenital heart defects observed in Kabuki syndrome. KMT2D also mediates coronary abnormalities in hypoplastic left heart syndrome via NOTCH signaling.
- **Cerebellar granule cell differentiation**: KMT2D temporally activates neuronal transcription factor genes to mediate cerebellar granule cell differentiation.
- **Tooth enamel development**: KMT2D regulates amelogenesis, and its disruption causes enamel defects.
- **Epithelial homeostasis**: KMT2D regulates p63 target enhancers to coordinate epithelial self-renewal, proliferation, and differentiation.

```mermaid
flowchart TD
    A["Extracellular Signals: Growth Factors, Cytokines"] --> B["Receptor Tyrosine Kinases / Cytokine Receptors"]
    B --> C["PI3K/AKT/mTOR Pathway"]
    B --> D["MEK/ERK Pathway"]
    C --> E["KMT2D Post-translational Modification"]
    D --> E
    
    E --> F["KMT2D Activation / Stabilization"]
    F --> G["KMT2D-COMPASS Complex Assembly"]
    G --> H["H3K4me1 Deposition at Enhancers"]
    H --> I["Recruitment of YBX1, EBF2, p300/CBP"]
    I --> J["Enhancer Activation & H3K27ac Deposition"]
    J --> K["Target Gene Transcription"]
    
    K --> L["Lineage-Specific Gene Expression"]
    K --> M["Tumor Suppressor Genes"]
    K --> N["Metabolic Genes"]
    K --> O["Immune Response Genes"]
    
    L --> P["Development & Differentiation"]
    M --> Q["Suppression of Tumorigenesis"]
    N --> R["Mitochondrial Respiration"]
    O --> S["Antiviral Immunity & T Cell Function"]
    
    E --> T["FBXW7-Mediated Degradation"]
    T --> U["Proteasomal Degradation"]
    
    style G fill:#f9f,stroke:#333,stroke-width:2px
    style H fill:#bbf,stroke:#333,stroke-width:2px
    style K fill:#bfb,stroke:#333,stroke-width:2px
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations in Kabuki Syndrome

Kabuki syndrome type 1 (KS1; OMIM #147920) is an autosomal dominant disorder caused by heterozygous germline loss-of-function mutations in KMT2D. The disorder is characterized by:

- **Distinctive facial features**: Long palpebral fissures with eversion of the lateral third of the lower eyelid, arched eyebrows with sparse lateral third, prominent ears, depressed nasal tip, and cleft lip/palate
- **Postnatal growth deficiency** and short stature
- **Intellectual disability** of variable severity
- **Skeletal abnormalities**: Brachydactyly, fifth finger clinodactyly, persistent fetal fingertip pads
- **Congenital malformations**: Congenital heart defects, renal anomalies, gastrointestinal malformations
- **Immunodeficiency**: Recurrent infections, autoimmune disorders, immune dysregulation
- **Endocrine abnormalities**: Hyperinsulinemic hypoglycemia, primary carnitine deficiency

The mutational spectrum of KMT2D in Kabuki syndrome is highly heterogeneous, comprising nonsense mutations, frameshift mutations, splice-site mutations, and missense mutations distributed throughout the gene. The majority of pathogenic variants are predicted to result in haploinsufficiency through nonsense-mediated decay or truncation of the protein. Large deletions and duplications account for a minority of cases.

**Recurrent mutation hotspots** include:

- **Exon 39**: This exon is a hotspot for pathogenic variants, and mutations in this region define a distinct clinical entity with a restricted phenotype that may lack the characteristic Kabuki facial features. The exon 39 region encodes a portion of the protein critical for NCOA6 interaction.
- **The SET domain**: Missense mutations in the catalytic SET domain abolish methyltransferase activity and are associated with classic Kabuki syndrome phenotypes.
- **The PHD fingers**: Mutations disrupting PHD finger structure impair chromatin binding and are pathogenic.

**Representative pathogenic variants** reported in the literature include:

| **Variant** | **Protein Change** | **Variant Type** | **Clinical Phenotype** | **Reference** |
|---|---|---|---|---|
| c.6341del | p.Gly2114Alafs*30 | Frameshift | Kabuki syndrome with ocular manifestations | |
| c.4168G>A | p.Ala1390Thr | Missense | Ultra-treatment-resistant schizophrenia | |
| c.4690G>A | p.Gly1564Arg (predicted) | Missense | Kabuki syndrome with autoimmune conditions | |
| c.13222C>T | p.Gln4408* | Nonsense | Kabuki syndrome with congenital heart disease | |
| c.16073_16074del | p.Leu5358Profs*9 | Frameshift | Kabuki syndrome with hepatic adenomatosis and HCC | |
| c.12415C>T | p.Arg4139* | Nonsense | Kabuki syndrome with GLILD | |
| c.13426C>T | p.Arg4476* | Nonsense | Kabuki syndrome with hearing impairment | |
| c.4690G>A | p.Gly1564Arg | Missense | Kabuki syndrome with thymoma and autoimmune polyendocrinopathy | |

### 4.2 Mosaic and Somatic Mutations

KMT2D mutations can occur as **postzygotic mosaicism**, where the pathogenic variant is present in only a subset of cells. Mosaic KMT2D mutations have been detected in Kabuki syndrome patients with milder or atypical phenotypes. DNA methylation profiling has proven valuable for validating postzygotic mosaicism and reclassifying variants of uncertain significance (VUS) in KMT2D.

### 4.3 Somatic Mutations in Cancer

KMT2D is among the most frequently mutated genes in cancer, with loss-of-function mutations occurring across a wide spectrum of malignancies:

| **Cancer Type** | **Mutation Frequency** | **Clinical Significance** | **Reference** |
|---|---|---|---|
| Diffuse large B-cell lymphoma (DLBCL) | ~30% | Poor prognosis; cooperation with CREBBP mutations | |
| Follicular lymphoma (FL) | ~70-80% | Early driver event; associated with FL progression | |
| Medulloblastoma (SHH subtype) | ~20-25% | Promotes metastasis; therapeutic vulnerability | |
| Triple-negative breast cancer (TNBC) | ~10-20% | Drives brain metastasis via MMP3 | |
| Lung squamous cell carcinoma (LUSC) | ~15-20% | Potential therapeutic target | |
| Pancreatic cancer | ~10% | Promotes tumor progression via LCD-mediated transcription | |
| Prostate cancer | ~10% | AR-dependent growth; therapeutic target | |
| Endometrial cancer | ~15% | Alters CDK-cyclin regulation of Rb | |
| Colorectal adenocarcinoma | ~10% | Immune microenvironment modulation | |
| Extranodal NK/T-cell lymphoma | ~20% | Poor prognostic factor | |
| Pheochromocytoma | ~10% | Recurrently mutated gene | |
| Adult-type granulosa cell tumors (aGCT) | ~15% | Associated with recurrence | |
| Upper tract urothelial carcinoma | ~20% | Expression correlates with location | |
| Head and neck squamous cell carcinoma | ~10-15% | Radiogenomic correlations | |

### 4.4 Genotype-Phenotype Correlations

Genotype-phenotype correlations in KMT2D-related disorders are emerging:

1. **Truncating mutations** (nonsense, frameshift) are associated with more severe Kabuki syndrome phenotypes, including congenital heart defects and intellectual disability.
2. **Missense mutations in the SET domain** are associated with classic Kabuki syndrome with characteristic facial features.
3. **Exon 38/39 mutations** define a distinct allelic disorder with a restricted phenotype, often lacking the typical Kabuki facial gestalt. These patients may present with isolated congenital heart defects or developmental delay without the characteristic facial features.
4. **Mosaic mutations** are associated with milder phenotypes and may escape clinical recognition.

### 4.5 Clinical Differentials and Diagnostic Considerations

The clinical diagnosis of Kabuki syndrome can be challenging due to phenotypic overlap with other genetic disorders. Key differential diagnoses include:

- **CHARGE syndrome**: Caused by CHD7 mutations; shares features of choanal atresia, ear malformations, and growth retardation. A patient with clinical CHARGE syndrome was found to harbor a KMT2D mutation, illustrating the phenotypic overlap.
- **KDM6A-related Kabuki syndrome type 2**: X-linked disorder with similar clinical features; caused by mutations in KDM6A (UTX).
- **TASP1-related disorder**: Caused by loss-of-function mutations in TASP1, which encodes an activator of KMT2A and KMT2D; presents with developmental delay, distinctive facial features, and congenital anomalies.
- **Rubinstein-Taybi syndrome**: Caused by CREBBP/EP300 mutations; shares intellectual disability and facial dysmorphism.

**Diagnostic approaches** include:

1. **Targeted gene panel sequencing** for KMT2D, KDM6A, CHD7, and related genes.
2. **Whole-exome sequencing (WES)** for patients with atypical presentations.
3. **DNA methylation profiling (episignature)** to classify VUS and detect mosaicism.
4. **Multimodal imaging** for ocular and otoradiological abnormalities.

## 5. Host-Pathogen & Viral Interactions

### 5.1 Merkel Cell Polyomavirus (MCV)

KMT2D interacts with the **Merkel cell polyomavirus (MCV)** in the pathogenesis of Merkel cell carcinoma (MCC). MCV is integrated into MCC tumor genomes, and integration sites frequently disrupt the KMT2D tumor suppressor gene. The integration of MCV into the KMT2D locus results in truncation mutations that inactivate KMT2D, contributing to tumorigenesis. This viral integration-mediated disruption of KMT2D represents a direct host-pathogen interaction that promotes cancer development.

### 5.2 Viral Oncoproteins and Immune Evasion

While direct interactions between KMT2D and viral oncoproteins have not been extensively characterized, KMT2D plays critical roles in antiviral immunity that indirectly influence host-pathogen interactions:

1. **Antiviral CD4+ T cell responses**: KMT2D coordinates antiviral CD4+ T cell responses through opposing effects on T follicular helper and cytotoxic gene expression. KMT2D deficiency impairs the generation of protective antibody responses during viral infection.
2. **CD8+ T cell survival**: KMT2D regulates naive CD8+ T cell activation-induced survival, which is essential for effective antiviral immunity.
3. **Immune evasion in cancer**: KMT2D mutations in cancer shape the tumor immune microenvironment, potentially influencing responses to immune checkpoint inhibitors. In colorectal adenocarcinoma, KMT2D mutations are associated with altered immune cell infiltration and drug sensitivity.

### 5.3 Bacterial Effectors and Immune Evasion

The role of KMT2D in immune cell function suggests that bacterial pathogens may exploit KMT2D pathways for immune evasion, although direct interactions between bacterial effectors and KMT2D have not been reported. KMT2D-deficient T cells exhibit altered integrin expression and impaired trafficking, which could affect the host response to bacterial infections. Additionally, KMT2D mutations in Kabuki syndrome are associated with immunodeficiency and recurrent infections, including granulomatous and lymphocytic interstitial lung disease (GLILD).

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 KMT2D as a Therapeutic Target

KMT2D presents a complex therapeutic landscape due to its dual role as a tumor suppressor and, in certain contexts, an oncogene. Therapeutic strategies targeting KMT2D can be categorized into:

1. **Inhibition of KMT2D enzymatic activity** (for cancers where KMT2D acts as an oncogene)
2. **Synthetic lethality approaches** (for cancers with KMT2D loss-of-function mutations)
3. **Epigenetic combination therapies** (targeting compensatory pathways)

### 6.2 KMT2D Inhibitors in Development

The C-terminal SET domain of KMT2D is responsible for its catalytic activity, and small-molecule inhibitors targeting this domain are under investigation. In prostate cancer, where high KMT2D expression is associated with reduced patient survival, KMT2D inhibitors have shown promise in preclinical studies. These inhibitors block H3K4 methylation, impairing AR-dependent gene expression and suppressing tumor growth in AR-dependent castration-resistant prostate cancer models.

### 6.3 Synthetic Lethality and Combination Strategies

For cancers with KMT2D loss-of-function mutations, direct targeting of KMT2D is not feasible. Instead, synthetic lethality approaches exploit vulnerabilities created by KMT2D deficiency:

1. **KDM5 inhibition**: KDM5 family demethylases remove H3K4me3/me2 marks. Inhibition of KDM5 in KMT2D-mutant lymphomas re-establishes H3K4 methylation and restores the expression of KMT2D target genes, offering a novel therapeutic strategy.
2. **LSD1 and OXPHOS inhibition**: Heterozygous KMT2D loss in medulloblastoma diminishes enhancer activity, rendering cells vulnerable to combinatorial inhibition of LSD1 (lysine-specific demethylase 1) and oxidative phosphorylation (OXPHOS).
3. **AKT inhibition**: KMT2D loss sensitizes prostate

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)